Cancer is a severe diseases causing millions of death worldwide every year. Cancer starts from a single cell and genetically transforms a normal cell in to tumour cell and is gradually spread to other cells. With the dramatic increase in the number of people affected by cancer, many pharmaceutical players started to invest on monoclonal antibodies. While the drugs are used for the treatment of cancer, drugs like chemotherapy agents have adverse side effects as they affect the normal cells as well along with cancerous cells. This prompted the increased usage of Monoclonal Antibodies for the treatment of cancer.
Monoclonal Antibodies having the potential to offer less toxic and efficient therapeutic alternatives to the patients have been emerging in the recent years. Monoclonal Antibodies are used to treat a wide array of diseases related to autoimmune, inflammatory and especially cancer. Monoclonal Antibodies (mAbs) are mono-specific antibodies bodies comprising of identical immune cells that are clones of a single parent cells and are directed to a specific cellular targets. Thus Monoclonal Antibodies are highly customizable due to its specific nature and can play a crucial role in eliminating the cancerous cell while sparing the normal cells during the cancer treatment. The monoclonal antibodies are proved to be more effective than chemotherapies and drugs for cancer treatment.
The dramatic increase of the number of cancer patients has led many pharmaceutical players to invest in monoclonal antibodies market. Increasing investment in research and development of genomic studies, technological advancements in genetic sequencing and target gene selection, specificity of monoclonal antibodies to target only the cancer cells with no side effects are the some of the driving forces of the market. Increased prevalence of cancer being the key driver for the monoclonal antibodies market, it is expected to grow lucratively in the next 5 years with the presence of strong products in the pipeline. However, there are few restraints for the growth of the market like high development cost being the major one. And also, stringent regulatory guidelines, long durations required for the research and development of antibodies, longer periods of clinical trials are some of the hurdles faced by the market.
The highly customizable nature of the monoclonal antibodies are attracting various organizations, research institutes and multinational companies to use it as a tool to cure cancer. The major players in the Cancer Monoclonal Antibodies Market are Amgen, Genmab, glaxosmithkline, Bristol Myers Squibb, Roche, Eli Lilly, Immunogen, Novartis, Seattle Genetics and Spectrum Pharmaceuticals.
About Market Data Forecast: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com
Contact: Abhishek Shukla Sales Manager (International Business Development) Market Data Forecast Direct Line: +1-888-702-9626 Mobile: +91 998 555 0206 Mail: abhishek@marketdataforecast.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
